Q2 could be slower as loading benefits fade away; COVID-19 offers opportunities
30/04/20 -"We have increased our FY20 earnings on the back of a better than expected favourable product mix (higher sales contribution from the Dupixent and Influenza vaccine). Also, we had been quite ..."
Pages
73
Language
English
Published on
30/04/20
You may also be interested by these reports :
24/04/24
The Q1 sales met the street’s expectations, although forex, off-patent drugs’ generic/biosimilar erosion and declining COVID-19 sales adversely ...
24/04/24
Ipsen started 2024 on a positive note with sales ahead of the company-compiled consensus. Double-digit growth was led by Neuroscience, Oncology, and ...
23/04/24
The Q1 results came in ahead of the consensus as growth was supported by healthy performances across all the focus areas. Consequently, the ...
17/04/24
Q1 sales exceeded expectations, driven by a strong performance from the Companion Animal segment. The Farm Animal segment was however held back by a ...